RAF1 and cancer: The modification of both the heterocyclic moiety and the distal pyridine ring of compound 5 led to the identification of sorafenib (c-Raf IC50 = 6 nM), which has been shown to be effective in both preclinical and clinical studies against several forms of human cancer (Lowinger et al., 2002).